Lilly reacquires drug it sold off 12 years ago.
2017 could be a bumper year for M&A – but Trump’s price control threats dominate
Allergan to co-develop Parkinson’s drug with Lysosomal Therapeutics
Biotech specialises in autoimmune disorder drugs.
Pharma M&A could surge in 2017, says report
David Ricks revamps organisation after trial disappointment.
Deal could be worth more than $1.5bn to AZ.
Reports suggest Sanofi could pay $30 billion for Swiss biotech.